Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
METAANALYSIS OF STUDIES OF THE CYP2D6 POLYMORPHISM IN RELATION TO LUNG-CANCER AND PARKINSONS-DISEASE
Autore:
ROSTAMIHODJEGAN A; LENNARD MS; WOODS HE; TUCKER GT;
Indirizzi:
UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL SHEFFIELD S10 2JF S YORKSHIRE ENGLAND UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL SHEFFIELD S10 2JF S YORKSHIRE ENGLAND
Titolo Testata:
Pharmacogenetics
fascicolo: 3, volume: 8, anno: 1998,
pagine: 227 - 238
SICI:
0960-314X(1998)8:3<227:MOSOTC>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
HYDROXYLASE GENE POLYMORPHISM; DEBRISOQUINE METABOLIC PHENOTYPE; OXIDATIVE POLYMORPHISM; CYTOCHROME-P450 CYP2D6; ALLELIC FREQUENCIES; RANDOMIZED TRIALS; SUSCEPTIBILITY; RISK; ASSOCIATION; GENOTYPE;
Keywords:
CYP2D6; LUNG CANCER; METAANALYSIS; PARKINSONS DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
81
Recensione:
Indirizzi per estratti:
Citazione:
A. Rostamihodjegan et al., "METAANALYSIS OF STUDIES OF THE CYP2D6 POLYMORPHISM IN RELATION TO LUNG-CANCER AND PARKINSONS-DISEASE", Pharmacogenetics, 8(3), 1998, pp. 227-238

Abstract

Studies of associations between the CYP2D6 polymorphism and susceptibility to specific diseases, particularly lung cancer and Parkinsonism,have produced conflicting results with respect to an under or overrepresentation of poor metabolizers. Accordingly, we have re-evaluated this primary research (18 studies on lung cancer and 18 on Parkinsonism)using meta-analysis. For lung cancer the median odds ratio (OR) was 0.69 (95% confidence interval (CI) 0.52-0.90), which differed significantly from unity (P < 0.007). A trial comprising 3000 patients and an equal number of control individuals would be required to demonstrate that this observation had arisen purely by chance (i.e. OR = 1), For Parkinson's disease, the analysis gave an OR of 1.32 (95% CI 0.98-1,78), which was of borderline statistical significance (P < 0,074). If the only individual study that was statistically significant was excluded, the P-value increased greatly to 0.489. A study of at least 500 patients and an equal number of control individuals giving the same value asthe current mean OR of 1.32 would be required to make the overall analysis statistically significant. In summary, poor metabolizers with respect to CYP2D6 show a small decrease in susceptibility to lung cancercompared with extensive metabolizers and it is hard to justify further studies. The relationship between the CYP2D6 polymorphism and lung cancer, as a determinant of individual susceptibility, is not appreciable (OR = 0.69) compared with that between smoking and lung cancer (OR > 11). Nevertheless, the epidemiological impact on the number of poor metabolizers who are protected from lung cancer may be considerable. With regard to Parkinson's disease, additional well designed studies may allow a definitive conclusion, although any risk for poor metabolizers is likely to be small and therefore of questionable clinical significance. An important lesson from the current review of studies is thatmuch time, effort, expense and patient inconvenience might have been avoided if more attention had been paid to appropriate study design, particularly in the selection of control groups. Pharmacogenetics 8:227-238 (C) 1998 Lippincott-Raven Publishers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 00:34:04